Frederick Munschauer, MD
At the 2016 CMSC Annual Meeting, Dr. Munschauer discussed the results of three studies that used real-world data to look at relapse rates, outpatients resource use, and costs related to patients taking subcutaneous interferon beta-1a as compared with other MS therapies.
VIDEO: Teriflunomide and dimethyl fumarate are comparable in relapsing-remitting MS
Adil Harroud, MDPublish date: February 9, 2018
VIDEO: Advanced practice providers take on many roles in MS carePublish date: February 7, 2018
VIDEO: Managing the alemtuzumab paradoxPublish date: February 3, 2018
VIDEO: Oral ozanimod shows promise for relapsing MSPublish date: February 3, 2018
Immunopathogenesis, diagnosis, and treatment of MS